Roche's oral selective oestrogen degrader fails in BCApril 25, 2022 - Roche’s previous claims that its oral selective oestrogen degrader giredestrant could be best in class have come to nothing. The group disclosed during its first-quarter results [ on Monday ] that the agent had failed the phase 2 Acelera trial in previously treated ER-positive Her2-negative breast cancer.
https://www.evaluate.com/vantage/articles/news/trial-results/roche-has-rare-breast-cancer-setback